Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Merck
Baxter
Colorcon

Last Updated: May 26, 2022

DEFINITY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Definity, and what generic alternatives are available?

Definity is a drug marketed by Lantheus Medcl and is included in one NDA. There are six patents protecting this drug.

This drug has forty-seven patent family members in fifteen countries.

The generic ingredient in DEFINITY is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

DrugPatentWatch® Generic Entry Outlook for Definity

Definity was eligible for patent challenges on July 31, 2005.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 4, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for DEFINITY
Drug patent expirations by year for DEFINITY
Drug Prices for DEFINITY

See drug prices for DEFINITY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for DEFINITY
Generic Entry Date for DEFINITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DEFINITY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 2
University of MichiganPhase 2
Institute of Liver and Biliary Sciences, IndiaN/A

See all DEFINITY clinical trials

US Patents and Regulatory Information for DEFINITY

DEFINITY is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of DEFINITY is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting DEFINITY

Lipid-encapsulated gas microsphere compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods and devices for preparation of ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Methods for making ultrasound contrast agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEFINITY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DEFINITY

See the table below for patents covering DEFINITY around the world.

Country Patent Number Title Estimated Expiration
Japan 3299745 See Plans and Pricing
Canada 2069759 LIPOSOMES UTILISES COMME AGENTS DE CONTRASTE DANS L'IMAGERIEA ULTRASONS (LIPOSOMES AS CONTRAST AGENTS FOR ULTRASONIC IMAGING) See Plans and Pricing
Canada 3025580 PROCEDES DE PRODUCTION D'AGENTS DE CONTRASTE D'ULTRASONS (METHODS FOR MAKING ULTRASOUND CONTRAST AGENTS) See Plans and Pricing
Japan H11508871 See Plans and Pricing
Germany 122007000024 See Plans and Pricing
Austria 180170 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DEFINITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 SPC018/2007 Ireland See Plans and Pricing SPC018/2007: 20071012, EXPIRES: 20190519
0712293 SPC/GB07/031 United Kingdom See Plans and Pricing PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
0712293 91325 Luxembourg See Plans and Pricing PRODUCT NMAE. LUMINITY; REGISTRATION DATE: 20060920
0712293 0790017-8 Sweden See Plans and Pricing PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
0712293 300267 Netherlands See Plans and Pricing 300267, 20140520, EXPIRES: 20190519
0712293 C300267 Netherlands See Plans and Pricing PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Johnson and Johnson
Merck
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.